In-depth equity research from the BestStocks desk — earnings breakdowns, valuation deep dives, and sector analysis behind the changes we detect.
Stock AnalysisJuly 21, 2026 · 13 min read
Danaher fell nearly 13% on July 21, 2026 despite beating on adjusted EPS and raising its full-year earnings guidance. The company tied that raise partly to completing the Masimo acquisition early — while cutting full-year core revenue growth guidance to 3–4% from 3–6% and marking bioprocessing down to mid-single-digit growth. The market paid for the organic line, not the inorganic one. Bioprocessing peers Repligen and Sartorius fell in sympathy while instrument makers rose, on a day the broad market was up ~1%.
Stock AnalysisJuly 20, 2026 · 18 min read
Hut 8 jumped about 11% on July 20, 2026 after a second 352 MW, 15-year, $9.8 billion lease fully commercialized its 1 GW Beacon Point campus in Texas — signed by the same unnamed tenant that took Phase 1 in May. The deeper significance is financing: Phase 1 was funded with $4.25 billion of non-recourse, Baa2-rated notes, and an anchor lease is the precondition for repeating that. But the move only round-trips a two-session drop, leaving the stock below where it closed on Wednesday.
Stock AnalysisJuly 18, 2026 · 11 min read
Alcoa closed down 6.1% on July 17, 2026 — far more than its aluminum peers or the metal itself. Its Q2 set a revenue record and grew adjusted EPS more than fivefold, but it missed an elevated Street bar and cut full-year alumina guidance after cyclone-related outages at its Pinjarra refinery. The drop confirmed an aluminum-surplus bear case analysts had already been pricing in, and it layers dilution and integration questions from the pending South32 acquisition on top.
Stock AnalysisJuly 17, 2026 · 11 min read
Cadence fell about 10% intraday on July 17, 2026 — far more than the broad chip group, which pared its morning losses. Market coverage tied the EDA pair's underperformance to Moonshot's Kimi K3, which the company says designed a 45nm chip in simulation using only open-source tools. It's an early, reported proof of concept, set against a broad semiconductor retreat — and it overwhelmed Cadence's own Rapidus AI partnership and Benchmark's $450 Buy call.
Stock AnalysisJuly 17, 2026 · 9 min read
Intuitive Surgical dropped about 13% intraday to a fresh 52-week low the morning after beating Q2 estimates. The catalyst was the outlook, not the quarter: full-year da Vinci procedure-growth guidance of 13.5–15.5% implies a second-half deceleration, with moderating U.S. demand and an ACA coverage headwind. A ~40x multiple left no room for it, and six firms cut targets within hours — while the rest of medtech barely moved.
Stock AnalysisJuly 16, 2026 · 10 min read
Bloom Energy dropped about 14% intraday on the same day IDF and Oaktree announced a $1.7 billion project financing to power Nebius's AI build-out. The move reads as 'sell the news' — profit-taking on a stock priced north of 250x EV/EBITDA, a fuel-cell-complex derating (FCEL −16%), and a broad AI-capex risk-off — with a thinly-detailed deal and the prior week's short-seller overhang in the background.
